| Is noise-induced cochlear neuropathy key to the generation of hyperacusis or tinnitus? AE Hickox, MC Liberman Journal of Neurophysiology, 2014 | 404 | 2014 |
| Auditory Brainstem Response Latency in Noise as a Marker of Cochlear Synaptopathy G Mehraei, AE Hickox, HM Bharadwaj, H Goldberg, S Verhulst, ... The Journal of Neuroscience 36 (13), 3755-3764, 2016 | 280 | 2016 |
| Translational issues in cochlear synaptopathy AE Hickox, E Larsen, MG Heinz, L Shinobu, JP Whitton Hearing research 349, 164-171, 2017 | 185 | 2017 |
| A murine model of neurofibromatosis type 2 that accurately phenocopies human schwannoma formation JR Gehlhausen, SJ Park, AE Hickox, M Shew, K Staser, SD Rhodes, ... Human molecular genetics 24 (1), 1-8, 2015 | 105 | 2015 |
| Global Analysis of Protein Expression of Inner Ear Hair Cells AE Hickox, ACY Wong, K Pak, C Strojny, M Ramirez, JR Yates, AF Ryan, ... Journal of Neuroscience 37 (5), 1320-1339, 2017 | 68 | 2017 |
| Divergent auditory-nerve encoding deficits between two common etiologies of sensorineural hearing loss KS Henry, M Sayles, AE Hickox, MG Heinz Journal of Neuroscience, 2019 | 34 | 2019 |
| Loss of LDAH associated with prostate cancer and hearing loss BB Currall, M Chen, RC Sallari, M Cotter, KE Wong, NG Robertson, ... Human Molecular Genetics, 2018 | 21 | 2018 |
| Loudness Perception of Pure Tones in Parkinson's Disease D Abur, AA Lupiani, AE Hickox, BG Shinn-Cunningham, CE Stepp Journal of Speech, Language, and Hearing Research 61 (6), 1487-1496, 2018 | 16 | 2018 |
| Genetic Medicine for Hearing Loss: OTOF as Exemplar AE Hickox, MD Valero, JT McLaughlin, GS Robinson, JA Wellman, ... Journal of the American Academy of Audiology 32 (10), 646-653, 2021 | 4 | 2021 |
| Nonclinical in vivo expression, durability of effect, biodistribution/shedding, and safety evaluations support planned clinical development of AK-OTOF (AAVAnc80-hOTOF Vector … AE Hickox, Y Gao, SP Francis, Y Asai, R Ng, H Chiang, E Andres-Mateos, ... American Society of Gene and Cell Therapy 25th Annual Meeting, 2022 | 3 | 2022 |
| Nonclinical In Vivo Expression, Durability of Effect, Biodistribution/Shedding, and Safety Evaluations Support Clinical Development of AK-OTOF (AAVAnc80-hOTOF Vector) for OTOF … AE Hickox, Y Gao, SP Francis, Y Asai, R Ng, H Chiang, E Andres-Mateos, ... MOLECULAR THERAPY 30 (4), 575-575, 2022 | | 2022 |
| Demonstration of Tolerability of a Novel Delivery Approach and Secreted Protein Expression Following Intracochlear Delivery of AK-antiVEGF (AAVAnc80-antiVEGF Vector) in Non … J Connelly, IK Hughes, AE Hickox, SP Francis, CA Shera, A Salt, ... MOLECULAR THERAPY 29 (4), 177-177, 2021 | | 2021 |
| Durable Recovery of Auditory Function Following Intracochlear Delivery of AK-OTOF (AAVAnc80-hOTOF Vector) in a Translationally Relevant Mouse Model of Otoferlin Gene (OTOF … AE Hickox, Y Gao, F Yu, Y Darcy, K Reape, SP Francis, YH Kim, S Davis, ... MOLECULAR THERAPY 29 (4), 276-277, 2021 | | 2021 |
MC LibermanSchuknecht Professor of Otolaryngology, Harvard Medical School, Massachusetts Eye and EarVerified email at meei.harvard.edu
